Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 01
Clopidogrel Tablet, Film Coated
Product Images NDC 13668-141
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 13668-141). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Torrent Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 02
Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 03
This is a table showing the cumulative event rate for cardiovascular death, myocardial infarction, and stroke for patients treated with Placebo versus Topidogrel bisuate and aspirin. The table presents the data over 12 months of follow-up. Other standard therapies were used as appropriate.*
Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 04
The text describes a figure showing the hazard ratio for patient baseline characteristics and on-study concomitant medications/interventions for the CURE study. The figure includes subgroups divided by age, gender, race, elevated cardiac enzymes, diabetes, previous MI, and previous stroke. The hazard ratio is displayed together with the number of patients and the percentage in favor of clopidogrel or placebo. The figure also includes confidence intervals for the hazard ratio.*
Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 05
This is a table showing Hazard Ratios for patient baseline characteristics and on-study concomitant medications/interventions for the CURE study. The table includes subgroups such as those who received Heparin/LMWH, different doses of Aspirin, GPIIb/IlIa Antag, Beta-Blocker and Ace Inhibitor. It shows the number of patients in each subgroup, the number of patients who received Clopidogrel versus Placebo, and which treatment was favored in each subgroup. The table also includes the overall Hazard Ratio (95% CT) without specifying what it is measuring.*
Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 06
This is a statistical analysis of the COMMIT study where the cumulative event rates for death are displayed in Figure 4. The study included patients who received either placebo or clopidogrel with aspirin, and the results show that the percentage of deaths was lower in the clopidogrel group (7.5%) compared to the placebo group (8.1%). The graph also shows a proportional risk reduction of 7% before the first five days of discharge. All treated patients received aspirin. The time frame of the study is up to 28 days from randomization.*
Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 07
The text describes a comparison between a placebo group and a group treated with clopidogrel, where all patients received aspirin. The results show that the proportion of patients with an event was lower in the clopidogrel group compared to the placebo group, with a proportional risk reduction of 9%.*
Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 08
This is a table titled "Effects of Adding Clopidogrel Bisulfate to Aspirin on the Combined Primary Endpoint across Baseline and Concomitant Medication Subgroups for the COMMIT Study". The table has multiple subgroups such as Gender, Age at entry (in years), hours since onset, fibrinolytic agent given, SBP (mmHg), and heart rate (bpm). For each subgroup, it shows the number of participants, the percentage of those who received clopidogrel versus those who received a placebo, and indicates whether clopidogrel or the placebo was favored. There is an odds ratio provided for the overall row only.*
Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 09
This is a graph displaying the cumulative event rate (percentage) for fatal or non-fatal vascular events over a period of 24 months, with follow-up intervals at 3, 12, 18, and 24 months. The graph appears to be comparing the effectiveness of Clopidogrel Bisulfate in preventing these types of events.*
Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 10
This appears to be a table with various medical conditions and corresponding percentages of patients taking either clopidogrel or aspirin. The conditions listed are stroke, MI (myocardial infarction), and PAD (peripheral artery disease), along with an overall category. The number of patients taking each medication for each condition is also listed, along with a percentage value. There is a column indicating which medication was favored, but without more context it is unclear what this refers to. There is also a column labeled "Hazard Ratio" with values listed, but again without context it is difficult to interpret.*
Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 11
Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 12
Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 13
This is a medication description for Clopidogrel tablets. Each tablet contains 75 mg of the active ingredient clopidogrel and is to be dispensed in a tight container resistant to moisture. The text also includes a prescription instruction for pharmacists to dispense the tablets with the accompanying prescribing information. There is also a mention of a product code NDC 13668-141-30.*
Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 14
Each tablet contains 87.875 mg of lopidogrel bisulfate. This bottle contains 30 tablets and has an NDC code of 13668-141-30. It is a USP standard 0.75 mg dosage. The tablets should be stored between 10 and 25 degrees Celsius (68-77 degrees Fahrenheit) and kept away from extreme temperature conditions. The container has a child-resistant top. Further information can be found on the accompanying insert. This medication is prescription-only and should only be dispensed by a pharmacist.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
